DCPH News and Press, Deciphera Pharmaceuticals Inc. From 04/22/20

There are plenty of intriguing biotech stocks on the market right now, and many of them are trading at a steep discount due to the coronavirus pandemic. However, no matter how exciting a company's prospects might be, investors still need to do their due diligence before choosing to invest in any...

Shares of Deciphera Pharmaceuticals ( DCPH ) have risen by 20% since my August 2019 update called the stock a Buy based on ripretinib's impressive showing in fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST). Targeted oncology has been one of my favored themes to capita...

Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) fell nearly 23% last month, according to data from  S&P Global Market Intelligence . Investors are concerned that the company's long-awaited transition to commercial operations will be delayed by the coronavirus pandemic. It's not a...

Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2019 Earnings Conference Call March 09, 2020, 04:30 PM ET Company Participants Jennifer Robinson - VP, IR Steven Hoerter - President and CEO Matthew Sherman - Chief Medical Officer Daniel Martin - Chief Commercial Officer Tucker Kelly...

Image source: The Motley Fool. Deciphera Pharmaceuticals, Inc.   (NASDAQ: DCPH) Q4 2019 Earnings Call Mar 9, 2020 , 4:30 p.m. ET Operator Continue reading

Deciphera Pharmaceuticals (NASDAQ: DCPH ): Q4 GAAP EPS of -$1.31 misses by $0.14 . More news on: Deciphera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- NDA for Ripretinib for the Treatment of Advanced GIST Accepted for Priority Review by U.S. FDA with PDUFA Date of August 13, 2020; Commercial Preparations Underway to Support Potential Approval and Launch - - INTRIGUE Pivotal Phase 3 Study of Ripretinib in Second-line GIST Expected t...

Healthcare Pulse Source: Bloomberg The fear of Coronavirus (Covid-19) has infected the stock market. The market's patience completely ran out this week as the Coronavirus news, which has continued to weigh heavily on the negative side, sent the market reeling in a feral pullback. Wha...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 9 th Annual SVB Leerink Global Healthcare Co...

Pulse Biosciences (NASDAQ: PLSE )  -44%  after disclosing NSE letter from FDA on CellFX system. More news on: Pulse Biosciences, Inc., CarGurus, Inc., LivePerson, Inc., Stocks on the move, , Read more ...